Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Harvard Scientific (HVSF)Hot$$- male impotency medicine -- Ignore unavailable to you. Want to Upgrade?

To: sly-1 who wrote (2798)	1/18/1998 11:04:00 PM
From: Cacaito	Respond to of 3906

The "financing" is for debt reduction. Maybe HVSF owes money to Waite and See for services to the company (salaries, consultants,...) and there is not cash money back to the company, just paper shuffle, nice trick it worked now I will get out with a smaller loss. Is the company going to have cash in hand from this? I doubt it. If they sell, then it is more cash for them, less "debt" for the company, and a new bunch of investors provinding the real money. Plus a huge dilution. Zonagen is not approved in Mexico. They conducted one clinical trial there. And probably some of that data could not be used for the NDA to the FDA.